Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Dr John Mendelsohn, Dr Richard Schilsky and Dr Richard Buller discuss the achievments of the WIN Consortium since it was first formed.
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer